Table 1.
Characteristics of first-line trials included.
| Study | Country/region | Treatment | Total no. pts | No. of EGFR+ pts (%) | No. of EGFR− pts (%) | No. of EGFR unknown pts (%) | Progression-free survival | Objective response | Disease control | Overall survival |
|---|---|---|---|---|---|---|---|---|---|---|
| First-line | HR (95% CI) | OR (95% CI) | OR (95% CI) | HR (95% CI) | ||||||
| WJTOG3405 (2010) | Japan | Gefitinib vs. Cis+D | 172 | 172 (100) | 0 | 0 | 0.49 (0.34–0.71) | 3.4 (1.6–7.4) | 3.8 (1.2–12.5) | 1.64 (0.75–3.59) |
| NEJ002 (2010) | Japan | Gefitinib vs. Car+Pa | 228 | 228 (100) | 0 | 0 | 0.32 (0.24–0.43) | 6.3 (3.6–11.2) | 2.1 (1.0–4.6) | 0.89 (0.63–1.26) |
| IPASS (2009) | East Asian | Gefitinib vs. Car+Pa | 1217 | 261 (21) | 176 (15) | 780 (64) | 0.74 (0.65–0.84) | 1.59 (1.25–2.01) | 0.70 (0.54, 0.92) | 0.90 (0.79–1.03) |
| First-SIGNAL (2012) | Korean | Gefitinib vs. Cis+G | 309 | 43 (14) | 54 (17) | 212 (69) | 1.20 (0.94–1.53) | 1.46 (0.93–2.28) | 0.56 (0.34, 0.94) | 0.93 (0.72–1.20) |
| Optimal (2011) | China | Erlotinib vs. Car+G | 154 | 154 (100) | 0 | 0 | 0.16 (0.10–0.26) | 8.6 (4.1–18.2) | 5.8 (1.6–21.3) | 1.07 (0.79–1.45) |
| EURTAC (2012) | Europe | Erlotinib vs. platinum+G/ or platinum+D | 173 | 173 (100) | 0 | 0 | 0.37 (0.25–0.55) | 7.9 (3.8–16.4) | 2.0 (1.0–3.9) | 1.04 (0.65–1.66) |
| LUX-Lung 3 (2012) | Global | Afatinib vs. Cis+Pe | 354 | 354 (100) | 0 | 0 | 0.58 (0.43–0.78) | 4.4 (2.6–7.3) | 2.1 (1.1–4.0) | 1.12 (0.73–1.72) |
| LUX-Lung 6 (2013) | Asian | Afatinib vs. Cis+G | 364 | 364 (100) | 0 | 0 | 0.28(0.20–0.39) | 6.8 (4.1–11.2) | 3.9 (2.1–7.3) | 0.95 (0.68–1.33) |
| Pooled HR (95% CI), p value | Pooled OR (95% CI), p value | Pooled OR (95% CI), p value | Pooled HR (95% CI), p value | |||||||
| 0.45 (0.30, 0.67), p<0.0001 | 4.09 (2.35, 7.15), p<0.0001 | 1.86 (1.01, 3.41), p=0.05 | 0.95 (0.86, 1.04), p=0.24 |
EGFR+ – EGFR mutation positive; EGFR− – EGFR mutation negative; Car – carboplatin; Cis – cisplatin; D – docetaxel; Pa – paclitaxel; Pe – pemetrexed; G – gemcitabine; N.A. – not available; OR – odd ratio; HR – hazard ratio; CI – confidential interval; Pts – patients.